These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18003831)

  • 1. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.
    Sinha S; Subramanian S; Proctor TM; Kaler LJ; Grafe M; Dahan R; Huan J; Vandenbark AA; Burrows GG; Offner H
    J Neurosci; 2007 Nov; 27(46):12531-9. PubMed ID: 18003831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS.
    Sinha S; Miller LM; Subramanian S; Burrows GG; Vandenbark AA; Offner H
    PLoS One; 2011; 6(7):e21868. PubMed ID: 21750737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG.
    Sinha S; Subramanian S; Emerson-Webber A; Lindner M; Burrows GG; Grafe M; Linington C; Vandenbark AA; Bernard CC; Offner H
    J Neuroimmune Pharmacol; 2010 Jun; 5(2):231-9. PubMed ID: 19789980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice.
    Vandenbark AA; Rich C; Mooney J; Zamora A; Wang C; Huan J; Fugger L; Offner H; Jones R; Burrows GG
    J Immunol; 2003 Jul; 171(1):127-33. PubMed ID: 12816990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch.
    Huan J; Subramanian S; Jones R; Rich C; Link J; Mooney J; Bourdette DN; Vandenbark AA; Burrows GG; Offner H
    J Immunol; 2004 Apr; 172(7):4556-66. PubMed ID: 15034073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
    Sinha S; Subramanian S; Miller L; Proctor TM; Roberts C; Burrows GG; Vandenbark AA; Offner H
    J Neurosci; 2009 Mar; 29(12):3816-23. PubMed ID: 19321778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Tolerogenic Artificial APC Durably Ameliorates Experimental Autoimmune Encephalomyelitis by Directly and Selectively Modulating Myelin Peptide-Autoreactive CD4
    Wan X; Pei W; Shahzad KA; Zhang L; Song S; Jin X; Wang L; Zhao C; Shen C
    J Immunol; 2018 Aug; 201(4):1194-1210. PubMed ID: 29987163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
    Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
    Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions.
    Dagkonaki A; Avloniti M; Evangelidou M; Papazian I; Kanistras I; Tseveleki V; Lampros F; Tselios T; Jensen LT; Möbius W; Ruhwedel T; Androutsou ME; Matsoukas J; Anagnostouli M; Lassmann H; Probert L
    Front Immunol; 2020; 11():575451. PubMed ID: 33329540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of encephalitogenic T cells with recombinant TCR ligands.
    Burrows GG; Adlard KL; Bebo BF; Chang JW; Tenditnyy K; Vandenbark AA; Offner H
    J Immunol; 2000 Jun; 164(12):6366-71. PubMed ID: 10843691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
    Choi JH; Lee MJ; Jang M; Kim EJ; Shim I; Kim HJ; Lee S; Lee SW; Kim YO; Cho IH
    PLoS One; 2015; 10(10):e0138592. PubMed ID: 26444423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates experimental autoimmune encephalomyelitis via an iNKT cell-dependent mechanism.
    Fujita M; Otsuka T; Mizuno M; Tomi C; Yamamura T; Miyake S
    Am J Pathol; 2009 Sep; 175(3):1116-23. PubMed ID: 19700760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells.
    Mendel I; Kerlero de Rosbo N; Ben-Nun A
    Eur J Immunol; 1995 Jul; 25(7):1951-9. PubMed ID: 7621871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Korean Red Ginseng and Ginsenoside-Rb1/-Rg1 Alleviate Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells and Upregulating Regulatory T Cells.
    Lee MJ; Jang M; Choi J; Chang BS; Kim DY; Kim SH; Kwak YS; Oh S; Lee JH; Chang BJ; Nah SY; Cho IH
    Mol Neurobiol; 2016 Apr; 53(3):1977-2002. PubMed ID: 25846819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
    Offner H; Sinha S; Wang C; Burrows GG; Vandenbark AA
    Rev Neurosci; 2008; 19(4-5):327-39. PubMed ID: 19145988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis.
    Carboni S; Aboul-Enein F; Waltzinger C; Killeen N; Lassmann H; Peña-Rossi C
    J Neuroimmunol; 2003 Dec; 145(1-2):1-11. PubMed ID: 14644025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.
    Kureshiro J; Miyamoto K; Tanaka N; Kusunoki S
    Neuroreport; 2009 May; 20(7):718-22. PubMed ID: 19402218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.
    Lee JH; Halperin-Sheinfeld M; Baatar D; Mughal MR; Tae HJ; Kim JW; Carter A; Lustig A; Snir O; Lavie G; Okun E; Mattson MP; Sredni B; Taub DD
    Neuromolecular Med; 2014 Jun; 16(2):292-307. PubMed ID: 24272426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
    Matejuk A; Adlard K; Zamora A; Silverman M; Vandenbark AA; Offner H
    J Neurosci Res; 2001 Sep; 65(6):529-42. PubMed ID: 11550221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.
    Matsumoto Y; Park IK; Hiraki K; Ohtani S; Kohyama K
    Immunology; 2009 Sep; 128(1 Suppl):e250-61. PubMed ID: 19175799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.